医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

BioChain Responds to Epigenomics’ Unilateral Termination of License Contract

2019年03月13日 AM06:43
このエントリーをはてなブックマークに追加


 

NEWARK, Calif.

BioChain, a US-based company, said today Epigenomics AG of Germany seriously violated the terms of an ongoing licensing contract by publicly announcing on March 6, 2019 the unilateral termination of BioChain’s licensing right of Septin9 marker in China. The termination of the contract by Epigenomics is not legally effective.

BioChain’s CEO, Grace Tian stated that according to the terms of the contract, disputes between the two parties require the parties to go through a mediation and arbitration process. BioChain filed a request with the contractually specified mediation and arbitration center on March 1, 2019 in accordance with the contract, before Epigenomics unilaterally terminated the contract.

BioChain and its affiliates, as the exclusive licensee of Septin9 marker in China, have diligently worked to expand its market position despite challenging market conditions, including the fact that one relevant patent of Epigenomics was invalidated in China and the news was publicly published in May 2018.

Tian said, “Epigenomics’ termination of the Septin9 contract has incurred damages to BioChain’s reputation and investment and BioChain will take further legal actions to protect its interests”.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190312005925/en/

CONTACT

Company: BioChain Institute Inc. 39600 Eureka Drive, Newark, CA 94560,
Tel 510-783-8588

Business Relations: Xiaoshan Wang, Tel 510-717-2859, E-Mail: br@biochain.com

同じカテゴリーの記事 

  • AtriCure已就在中国销售AtriClip®器械获得监管批准
  • ベイジーン、米国に生物製剤製造および臨床研究開発の旗艦施設を開設し、世界のより多くの患者に医薬品を届けるためのグローバルな拡大を継続
  • KBIバイオファーマがFDA検閲を通過、世界的な大手製薬会社との商業契約を延長・拡大
  • 继成功通过FDA检查后,KBI Biopharma续签并扩大了与全球领先制药公司的商业合同
  • BCF, BREF and TBG Companies Seek Global Financial Support to Establish 1000s of Best Cure Pro Health and Medical Centers